TY -的T1 -人类脂多糖模型提供机械和治疗见解系统性炎症和肺JF -欧洲呼吸杂志》乔和J - 10.1183/13993003.01298 -2019欧元SP - 1901298 AU -布鲁克斯,丹尼尔AU -巴尔,劳拉·c . AU - Wiscombe莎拉AU - McAuley,丹尼尔·f . AU -辛普森,a .约翰AU -罗斯特朗说道,N2 -炎症是脓毒症和急性呼吸窘迫综合征(ARDS)发病机制中的一个重要特征。脓毒症和急性呼吸窘迫综合征仍然与高死亡率相关。一个关键的促成因素是对人类肺部和全身炎症早期事件的基本理解，这在临床实践中很难研究，因为它们先于患者向医疗服务机构介绍。脂多糖(LPS)是革兰氏阴性细菌外膜的组成部分，是脓毒症中炎症和宿主反应失调的触发器。人类脂多糖模型向健康志愿者输送少量脂多糖，引发炎症反应，并提供了一个研究人类早期炎症的窗口。这使得生物学/机械学上的见解得以形成，新的治疗策略也可以在一个可控的、可重复的环境中从一个确定的时间点进行测试。我们回顾了人类脂多糖模型的使用，重点关注通过研究静脉和肺内脂多糖挑战的反应所获得的潜在机制。在考虑设计未来人类脂多糖研究时应考虑的因素之前，我们先讨论可能影响对脂多糖反应的变量。脚注:这份手稿最近已被《欧洲呼吸杂志》接受发表。在我们的制作团队进行编辑和排版之前，它以可接受的形式在这里出版。 After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online. Please open or download the PDF to view this article.Conflict of interest: Dr. Brooks has nothing to disclose.Conflict of interest: Dr. Barr has nothing to disclose.Conflict of interest: Dr. Wiscombe has nothing to disclose.Conflict of interest: Dr. McAuley reports personal fees from Peptinnovate, personal fees from Bayer, grants from NIHR, Wellcome Trust and other funders, personal fees from GlaxoSmithKline, other from GlaxoSmithKline, personal fees from Boehringer Ingelheim, personal fees from SOBI, outside the submitted work; In addition, Dr. McAuley has a patent Patent for novel treatment for ARDS issued to Queen's University Belfast.Conflict of interest: Dr. Simpson has nothing to disclose.Conflict of interest: Dr. Rostron has nothing to disclose. ER -